News

August 3, 2018

Gazyva Infusion Could Be Shorter for Some NHL Patients, Study Finds

News

Shortening the time needed for an infusion of Gazyva (obinutuzumab) did not affect the safety of Japanese patients with previously untreated CD20-positive B-cell non-Hodgkin’s lymphoma, a new study shows. “Safety, tolerability ... Read more

August 2, 2018

Venclexta Triple Combo in NHL Patients Produces Long-lasting Responses in Phase 1 Trial

News

A combination of Venclexta (venetoclax), bendamustine, and Rituxan (rituximab) is tolerable and produces long-lasting responses in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), according to a Phase 1 trial. The study, “Venetoclax, bendamustine, ... Read more

August 1, 2018

Ranimustine-based Conditioning Regimen Before Stem Cell Transplant Effective in DLBCL Patients, Study Suggests

News

A chemotherapeutic regimen that includes high-dose ranimustine may be used to prepare patients for a stem cell transplant, ultimately leading to high survival rates in patients with relapsed or high-risk ... Read more

July 31, 2018

Dietary Supplement with Probiotics, Digestive Enzymes May Protect Gut from Chemotherapy Side Effects

News

Taking a dietary supplement with probiotics and digestive enzymes helped prevent damage to the gut’s microbial community from chemotherapy, a recent study suggests. The study, “Protection from chemotherapy- and antibiotic-mediated ... Read more

July 30, 2018July 31, 2018

Revlimid-Rituxan Combo May Replace Chemo, Delay Decline for Some Lymphoma Patients, Phase 3 Trial Shows

News

Adding Revlimid (lenalidomide) to Rituxan (rituximab) in the treatment of follicular lymphoma and marginal zone lymphoma patients who failed at least one prior therapy significantly delays disease progression or death, a Phase 3 ... Read more

July 27, 2018

BeiGene’s Therapy Candidate Appears to Eliminate Tumors in Half of Hodgkin’s Patients in Phase 2 Trial

News

BeiGene‘s immunotherapy candidate tislelizumab was shown to eliminate tumors in 50% of patients with classical Hodgkin’s lymphoma who had failed to respond to their most recent treatment, according to preliminary results of a Phase ... Read more

July 26, 2018

Velcade-based Therapy Effective in Certain East Asian Mantle Cell Lymphoma Patients, Study Finds

News

A treatment combination including Velcade (bortezomib) was seen to be more effective than the standard R-CHOP chemotherapy in East Asian patients with mantle cell lymphoma (MCL) who cannot undergo a stem ... Read more

July 24, 2018

CLR 131 Significantly Reduces DLBCL Patients’ Tumor Size in Phase 2 Trial

News

The investigative drug CLR 131 all but eliminated tumor cells in one-third of diffuse large B-cell lymphoma (DLBCL) patients treated in a Phase 2 trial, and is showing promise in other kinds ... Read more

July 20, 2018

Adding Imbruvica to R-CHOP Does Not Improve Outcomes for Newly Diagnosed DLBCL Patients, Phase 3 Trial Shows

News

Adding Imbruvica (ibrutinib) to a standard chemotherapy regimen does not improve outcomes for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma (NHL), a Phase 3 trial ... Read more

July 19, 2018

Study Examines Prescription Rates for Rituximab Biosimilars in European NHL Patients

News

European patients with non-Hodgkin’s lymphoma (NHL) are more likely to receive rituximab biosimilars if they are fitter, have indolent disease, or follicular lymphoma, according to a new study. The study, “Treatment approach for ... Read more